Form 4: Gilead CFO Sells 2,500 Shares Under 10b5-1 Plan

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 2,500 shares of common stock for $125.23 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (GILD), disposed of 2,500 shares of common stock.
• The transaction occurred on November 17, 2025, at a price of $125.23 per share.
• Following this sale, Dickinson directly owns 154,555 shares of Gilead Sciences common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

Sentiment

Score: 5

Explanation: A routine insider sale under a 10b5-1 plan is generally neutral. It is not inherently positive or negative for the company's operational performance or future prospects.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, which indicates a planned sale rather than an immediate reaction to new information, potentially reducing concerns about insider trading.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the officer's direct stake in the company.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

Insider transactions, particularly sales, are common in the biotechnology and pharmaceutical industries, often for personal financial planning or diversification. The use of a 10b5-1 plan is a standard practice for executives to manage their stock holdings while adhering to insider trading regulations.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a common and accepted practice across all industries, including pharmaceuticals.
• The volume of shares sold (2,500) represents a small fraction of the CFO's total holdings (154,555 shares remaining), which is typical for routine diversification or liquidity events rather than a significant loss of confidence.

Related Party Transactions

• The transaction involves the Chief Financial Officer selling company stock, which is a related party transaction.

Stakeholder Impact

• Shareholders may view the sale neutrally due to the 10b5-1 plan, or slightly negatively as it reduces insider ownership. However, the small percentage of total holdings sold suggests minimal impact on confidence.
• Employees, customers, suppliers, and creditors are unlikely to experience any direct impact from a routine insider stock sale.

Key Dates

Recommendation

This Form 4 filing reports a routine insider stock sale by the CFO under a pre-arranged 10b5-1 plan. Such transactions are common for executive compensation and personal financial planning and typically do not indicate a change in the company's fundamental outlook or performance. Therefore, it provides no new information that would warrant a change in investment recommendation based solely on this filing. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Gilead Sciences, GILD, Andrew D. Dickinson, CFO, Insider Sale, Form 4, 10b5-1 Plan, Stock Transaction, Pharmaceutical, Biotechnology